Collaborative Efforts in Biosimilar Development
MS Pharma Group, a prominent name in the pharmaceutical sector within the MENA region, has forged a significant partnership with Hetero Group, a globally recognized pharmaceutical entity. This collaboration focuses on the localization of five established biosimilars, delivering vital advancements in therapeutic areas such as oncology, immunology, and hematology.
Implementing the Partnership
The exclusive agreement is set to be executed through El Kendi, MS Pharma's affiliate in Algeria, alongside Hetero Biopharma, a subsidiary of Hetero Group. This collaboration marks a pivotal moment for Hetero as it establishes its first local partnership in the country. Such efforts symbolize a major stride towards enhancing Algeria's biopharmaceutical ecosystem. Together, the combined efforts of both companies are projected to represent a robust total market value of approximately USD 45 million in Algeria within the coming years, following a thoughtful approach centered around localization and technology transfer.
Shared Vision for Healthcare Improvement
Kalle Känd, the CEO of MS Pharma Group, expressed his enthusiasm about the partnership, stating, "We are pleased to collaborate with a global partner like Hetero, with whom we share a long-term commitment to knowledge transfer and improving healthcare outcomes for patients in the region. This collaboration reflects our ongoing commitment to expanding patient access to trusted and affordable biologic treatments while supporting sustainable local healthcare systems. Strategic partnerships like this enable us to build durable regional capabilities and create meaningful, long-term impacts for patients and health systems across the MENA region."
Echoing this sentiment, Dr. Vamsi Krishna, MD of Hetero Group, mentioned, "At Hetero, we are guided by a strong commitment to ensuring access to high-quality and affordable medicines for patients across the globe. Partnering with MS Pharma, a well-established healthcare leader in the Middle East, marks an important milestone in advancing healthcare delivery and addressing unmet medical needs throughout the region and other key markets."
About MS Pharma and Hetero
MS Pharma stands as a leading pharmaceutical company focused on developing and distributing a wide variety of both generic and biologic therapies across the MENA area. With its headquarters in Amman, Jordan, MS Pharma operates five manufacturing facilities across Jordan, Algeria, and Saudi Arabia, which includes a state-of-the-art biologics plant. The company is committed to serving the broader MENA market and employs over 2,000 professionals across 12 countries.
On the other hand, Hetero is recognized globally for its role in manufacturing Active Pharmaceutical Ingredients (APIs) and generic formulations. Dedicated to transforming scientific advances into affordable therapies, Hetero works with various multinational pharmaceutical companies and is expanding its reach across over 145 countries. The company, established in Hyderabad, India, boasts a workforce exceeding 30,000 individuals committed to improving access to essential medicines worldwide.
Moreover, Hetero Biopharma, a significant subsidiary of Hetero, leads the charge in biosimilars development, focusing on enhancing global access to crucial therapies through its vast expertise in pharmaceutical research, production, and marketing.
Frequently Asked Questions
What is the main goal of the MS Pharma and Hetero partnership?
The partnership aims to localize five established biosimilars in key therapeutic areas, enhancing patient access to affordable treatments.
Where will the partnership's implementation take place?
The collaboration will be executed through El Kendi in Algeria and Hetero Biopharma.
How much is the projected market value of this collaboration?
The combined portfolio is projected to represent a market value of approximately USD 45 million in Algeria by 2024.
Who are the key executives involved in this partnership?
Kalle Känd, CEO of MS Pharma, and Dr. Vamsi Krishna, MD of Hetero Group, are the primary executives highlighting the values of this collaboration.
What does MS Pharma specialize in?
MS Pharma specializes in the development, production, and distribution of generic and biologic therapies across the MENA region.
